Search
Adecatumumab
go.drugbank.com/drugs/DB05006InvestigationalAdecatumumab is a recombinant human monoclonal antibody of the IgG1 subclass with a binding specificity to epithelial cell adhesion molecule (EpCAM). … EpCAM (CD326) is a cell surface protein that is frequently expressed at high level on most solid tumor types, including prostate, breast, colon, gastric, ovarian, pancreatic and lung cancer.
BW-A 58C
go.drugbank.com/drugs/DB06740ExperimentalBW-A 58C, also known as 2-(4-tert-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone, is an experimental naphthoquinone antimalarial drug which undergoes extensive alkyl hydroxylation to a single t-butylhydroxy … metabolite in man in vivo and also in human liver microsomes, where this is catalysed primarily by a 54 kDa CYP2C9 form of cytochrome P450, P450hB20-27.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 InhibitorsVeru-111
go.drugbank.com/drugs/DB16462InvestigationalVERU-111, an investigational drug intended for various therapeutic uses, was under investigation in clinical trials NCT04842747, NCT03752099, NCT04388826, NCT04844749, NCT05008510, and NCT05079360. … These trials aimed to evaluate its efficacy, safety, and tolerability in conditions such as SARS-CoV-2 infection, metastatic castration-resistant prostate cancer (mCRPC), respiratory distress syndrome
Protocatechualdehyde
go.drugbank.com/drugs/DB11268ApprovedAlso known as protocatechuic aldehyde, protocatechualdehyde is a naturally-occuring phenolic aldehyde that is found in barley, green cavendish bananas, grapevine leaves and root of the herb S. miltiorrhiza
Synonyms: Rancinamycin IVEthambutol
go.drugbank.com/drugs/DB00330ApprovedInvestigationalEthambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and [pyrazinamide] in the treatment of pulmonary tuberculosis. … [A229048] It was developed out of a need for therapies active against isoniazid resistant strains of _Mycobacterium tuberculosis_.[A229048] Ethambutol was granted FDA approval on 6 November 1967.
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 InhibitorsNaldemedine
go.drugbank.com/drugs/DB11691ApprovedInvestigationalNaldemedine is an opioid receptor antagonist [FDA Label]. … It is a modified form of [DB00704] to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier.
Cenobamate
go.drugbank.com/drugs/DB06119ApprovedInvestigationalCenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures. … [A188442,L10653] The exact mechanism of action has not been described in the literature, though it positively modulates GABA<sub>A</sub> and inhibits voltage gated sodium channels.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InducersMeclizine
go.drugbank.com/drugs/DB00737ApprovedInvestigationalMeclizine is a histamine H1 antagonist with antiemetic and antivertigo properties. … [L6760] Commonly marketed under the brand name Antivert in the U.S., meclizine is available as oral tablets.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesNGX267
go.drugbank.com/drugs/DB05152InvestigationalNGX267 is a muscarinic agonist. It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.
Concizumab
go.drugbank.com/drugs/DB12820ApprovedInvestigationalConcizumab is a humanized IgG4 monoclonal antibody targeting the Kunitz-2 domain of tissue factor pathway inhibitor (TFPI), a key regulator of the coagulation cascade. … [L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors.